Abstract 238P
Background
The EV-301 trial showed the efficacy of Enfortumab-Vedotin (EV) in the 3rd-line therapy for metastatic Urothelial Carcinoma (mUC) previously treated with platinum-combined chemotherapy and immune-checkpoint inhibitor. Here we showed an initial report of EV in our institution.
Methods
25 patients (Pts) with mUC received EV from January 2021 to July 2023 at our institution. EV was administered 10mg/kg weekly until disease progression. Whole-body CT scan was performed every two months(Ms). We retrospectively evaluated progression free survival based on RECIST version 1.1 as efficacy and adverse events (AEs) rate based on the National Cancer Institute CTCAE, version 4.03 as safety.
Results
Of 25 patients (Pts), with median age of 73 (54-85), 16 (64%) Pts had bladder tumor, 9(36%) Pts had upper urinary tract, 1 Pt had both upper and lower urinary tract as primary. 18(72%) Pts had lymph node metastasis (Mets), 14(56%) Pts had lung Mets, 5 (20%) Pts had liver Mets 4 (16%) Pts had bone Mets. 5(20%) Pts had 4 regimens, 7(28%) Pts had 3 regimens and 13(52%) Pts had 2 regimens of pre-treated systemic therapy for mUC. During the median follow-up period of 7.0 (2.1-16.2) Months, 9 (36%) Pt had died. The best response during follow-up period was CR in2(8%), PR in 11(44%), SD in 11(44%) and PD in1(4%) Pts. Median PFS was 10.5 Ms and OS was 13.0. 8 Severe AEs (more than Grade3) was occurred in 8 (32%) Pts, derimatosis was the highest occurrence AE and 65% patients had ermatosis. OS of patiets with prior taxane therapy was significantly worse than that of patients without prior taxane therapy (11.4M vs 14.1M, p=0.027).
Conclusions
Initial report of Enfortumab-Vedotin resulted in a median PFS of 10.5 Ms and 20% severe AE, which was as safe and effective as the report from clinical trial. OS of patients pre-treated with taxane therapy was significantly worse than that of patients without prior taxane therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract